• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Diamyd Medical

1.03 SEK

-3.56 %

Less than 1K followers

DMYD B

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
-3.56 %
-9.49 %
-92.71 %
-90.85 %
-89.78 %
-89.15 %
-87.40 %
-96.55 %
-65.70 %

Diamyd Medical is active in diabetes research. The company has developed a vaccine that contains the active ingredient and molecule GAD, a substance that has the potential to be an important part of the prevention of diabetes treatments in the future. The company has operations on a global level with the largest presence in the Nordic region. The headquarters are located in Stockholm.

Read more
Market cap
159.63M SEK
Turnover
413.1K SEK
Revenue
130K
EBIT %
-140,953.85 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Press releases
ShowingAll content types

Forum discussions
The intention was to publish the report before the readout, but the new financing package complicated things so much that practically everything had to be recalculated and models updated. On the other hand, the new financing package combined with market movements led to a heuristically...
3/30/2026, 2:53 PM
by Gubrick
9
To all you investors who believed in diabetes treatment drugs and lost your money in Diamyd, I recommend turning your gaze to a company called Nektar - $NKTR. They have a very interesting diabetes trial underway with a drug that targets Tregs, aiming to restore the body’s own immune...
4/23/2026, 11:15 AM
by SeekingAlpha
8
New information has come out, nothing positive. diamyd.com Diamyd Medical discontinues DIAGNODE-3 following evaluation confirming...
4/10/2026, 6:40 PM
6
There’s no point in selling in this bankruptcy. It still amazes me how the difference can be so radical compared to previous data that it’s not even worth continuing the study to the end. The probability that previous positive results were just a coincidence is quite small, isn’t...
4/13/2026, 9:38 AM
4
Good to know, the expenses stop running and they can do the trial’s autopsy. I’ll hold the earthly remains of the position out of academic interest.
4/10/2026, 7:28 PM
by Clark kent
4
Ulf stepped down from the CEO role after ten years. He was replaced by Diamyd founder, chairman of the board, and former CEO, Anders Essen-Möller. Anders is already a respectable 85 years old and founded Diamyd when his daughter fell ill with type 1 diabetes. A recent interview about...
4/27/2026, 11:35 AM
3
Great find! If you’re up for it, this might be the place for a new thread—just remember to tag it as comprehensively as possible, otherwise the thread might not be found. Regardless, the drug seems to be quite far along already, and there seems to be a market for it.
4/29/2026, 4:58 PM
by Hawkmountdiver
2
Read more on our forum
Revenue and EBIT-%

Revenue K

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
7.10
2026

Annual report '26

3.12
2026

General meeting '26

Regulatory press release25.06.2026, 08.30

Diamyd Medical AB: Mathias Skalmstad new CFO at Diamyd Medical

Diamyd Medical
Press release24.06.2026, 13.34

DNB Carnegie Access: Diamyd Medical: A difficult reset, but not an empty hand – Q3 2025/26 review

Diamyd Medical
Regulatory press release24.06.2026, 08.15

Diamyd Medical AB: Quarterly Report 3 25/26

Diamyd Medical

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release23.06.2026, 08.30

Diamyd Medical AB: Diamyd Medical provides update on Strategic Review

Diamyd Medical
Regulatory press release18.06.2026, 08.30

Diamyd Medical AB: Diamyd Medical announces update regarding interim CFO

Diamyd Medical
Regulatory press release11.06.2026, 08.55

Diamyd Medical AB: Diamyd Medical receives Notice of Allowance for Key Precision Medicine Patent

Diamyd Medical
Regulatory press release05.06.2026, 08.30

Diamyd Medical AB: Diamyd Medical provides update on ongoing Activities

Diamyd Medical
Regulatory press release22.05.2026, 08.30

Diamyd Medical AB: Diamyd Medical announces that Niklas Axelsson has decided to leave his position as CFO to take on a new role in another company

Diamyd Medical
Press release20.05.2026, 09.59

DNB Carnegie Access: Diamyd Medical: GMP milestone for Umeå facility

Diamyd Medical
Regulatory press release20.05.2026, 08.30

Diamyd Medical AB: Diamyd Medical receives GMP certification and manufacturing authorization for biological investigational medicinal products for human use

Diamyd Medical
Regulatory press release11.05.2026, 08.30

Diamyd Medical AB: Diamyd Medical provides an update on strategic review and financial position

Diamyd Medical
Press release05.05.2026, 12.33

DNB Carnegie Access: Diamyd Medical: GMP progress and latest news flow

Diamyd Medical
Regulatory press release05.05.2026, 08.30

Diamyd Medical AB: Diamyd Medical strengthens its position in the manufacturing of biological medicines - positive feedback from the Swedish Medical Products Agency

Diamyd Medical
Regulatory press release24.04.2026, 10.30

Diamyd Medical AB: Diamyd Medical announces governance and leadership update

Diamyd Medical
Regulatory press release23.04.2026, 11.15

Diamyd Medical AB: Diamyd Medical announces governance and leadership changes

Diamyd Medical
Press release13.04.2026, 08.59

DNB Carnegie Access: Diamyd Medical: Discontinues DIAGNODE-3 and initiates strategic review

Diamyd Medical
Regulatory press release10.04.2026, 19.10

Diamyd Medical AB: Diamyd Medical discontinues DIAGNODE-3 following evaluation confirming futility; initiates strategic review

Diamyd Medical
Regulatory press release08.04.2026, 15.10

Diamyd Medical AB: Bulletin from Diamyd Medical's Extraordinary General Meeting 2026

Diamyd Medical
Press release31.03.2026, 06.19

DNB Carnegie Access: Diamyd Medical: Awaiting clarity on next steps – valuation reset

Diamyd Medical
Press release30.03.2026, 17.00

DNB Carnegie Access: Diamyd Medical - DIAGNODE-3 interim readout

Diamyd Medical